Last reviewed · How we verify
Sincalide (SINCALIDE)
Sincalide works by binding to cholecystokinin receptors in the pancreas, stimulating the release of digestive enzymes.
At a glance
| Generic name | SINCALIDE |
|---|---|
| Sponsor | Bracco |
| Drug class | Cholecystokinin Analog [EPC] |
| Target | Cholecystokinin receptor type A |
| Modality | Recombinant protein |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
| First approval | 1976 |
Mechanism of action
When injected intravenously, sincalide stimulatesgallbladder contraction and reduction in size. The evacuation of bilethat results is similar to that which occurs physiologically in responseto endogenous cholecystokinin. Sincalide also stimulates pancreaticsecretion and intestinal motility causing pyloric contraction andslows gastric emptying.Concurrent administration of sincalide with secretin increases boththe volume of pancreatic secretion and the out-put of bicarbonateand enzymes. This combined effect of secretin and sincalide permitsthe assessment of specific pancreatic function through measurementand analysis of the duodenal aspirate.
Approved indications
- Diagnostic Test for Pancreas Function
- Diagnostic aid
Common side effects
- Gastrointestinal effects
- Diarrhea
- Nausea
- Abdominal or stomach pain
- Cramps
- Discomfort
- Dizziness
- Flushing
- Redness of skin
- Headache
- Increased sweating
- Numbness
Key clinical trials
- POTS-FLOW: Interplay Between Gut Hormones and Autonomic Postprandial Blood Flow Regulation in Patients With POTS (NA)
- Mechanisms and Targeted Therapy of Airway Basal Cell Dysfunction in Bronchiolitis Obliterans Syndrome (NA)
- Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986278 in Healthy Male Participants (PHASE1)
- Thyroid Hormones Homeostasis and Energy Metabolism Changes During Stimulation of Endogenously Secreted Bile Acids (BAs) (PHASE3)
- A Study Evaluating the Effect of Albiglutide on Gallbladder Emptying in Healthy Subjects (PHASE4)
- Dose Response of Intravenous Sincalide(CCK-8) for Gallbladder Emptying (NA)
- Impact of Two Genetic Variants of OATP1B3 or MRP2 or Rifampin on Systemic Disposition and Biological Efficacy of CCK-8 (PHASE1)
- The Impact of Gall Bladder Emptying and Bile Acids on the Human GLP-1-secretion (NA)
Patents
| Patent | Expiry | Type |
|---|---|---|
| 11737983 | 2038-04-20 | Formulation |
| 11318100 | 2038-04-20 | Formulation |
| 11110063 | 2038-04-20 | Formulation |
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sincalide CI brief — competitive landscape report
- Sincalide updates RSS · CI watch RSS
- Bracco portfolio CI